Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis

Inclusion Criteria:

1. Written informed consent and legal representative's permission for study
participation obtained prior to beginning of participation in the study.

2. Age ≥6 to <18 years old.

3. Established diagnosis of active moderate-to-severe plaque psoriasis defined as a
PASI score ≥ 10, body surface area (BSA) involvement of ≥10% and PGA score ≥ 3 only
or with concomitant psoriatic arthritis.

4. Failure or intolerance of prior psoriasis treatment.

5. Patient was prescribed with secukinumab within 4-16 weeks before inclusion.

6. Decision for secukinumab prescription was made by the attending physician according
to the approved national label during routine clinical practice, regardless of this
non-interventional study conduct.

Exclusion Criteria:

1. Known or suspected severe hypersensitivity for secukinumab, formulation excipients,
or injection device components (i.e., latex).

2. History of chronic recurrent infection.

3. Clinically significant infection exacerbation, including active tuberculosis.

4. Age <6 years or ≥18 years.

5. Pregnancy and breastfeeding.

6. Patients participating in parallel in an interventional clinical trial.

7. Patients participating in parallel in other Novartis-sponsored non-interventional
study generating primary data for secukinumab.

8. Patients within the safety follow-up phase of interventional study.

9. Active inflammatory bowel disease at inclusion.

10. Patients who received any vaccine within 4 weeks prior to secukinumab initiation.

11. Any medical or psychological condition in the investigator's opinion which may
prevent the study participation.